Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat in Uncontrolled and Resistant Hypertension
2023-505499-32-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of baxdrostat in hypertension (HTN) and resistant hypertension (RH) (3 arms), sponsored by AstraZeneca. Started Mar 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on 2023-505499-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505499-32-00.